Theravance Biopharma, Inc.
TBPH
$17.06
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.56% | -108.08% | 1,588.08% | -93.41% | 503.82% |
| Total Depreciation and Amortization | 0.42% | -4.58% | 7.04% | 4.30% | -2.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 414.39% | -75.05% | -29.20% | 190.59% | -278.86% |
| Change in Net Operating Assets | -109.72% | 204.76% | -328.80% | -110.70% | 203.82% |
| Cash from Operations | -109.50% | 1,308.43% | 6.82% | -103.13% | 383.45% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -214.85% | 8,724.33% | 100.59% | -176.74% | -218.26% |
| Cash from Investing | -214.85% | 8,844.39% | 100.59% | -176.48% | -218.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 371.78% | -50.61% | 75.54% | -- | -100.00% |
| Repurchase of Common Stock | 63.84% | -193.99% | -191.89% | -34.79% | 42.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 82.66% | -274.04% | -272.75% | 20.48% | 41.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.81% | 1,826.64% | 93.50% | -162.55% | 135.27% |